In 2022, COVAX’s efforts targeting long-term COVID-19 impact and beyond, transitioned into the “mRNA Technology Transfer Programme”, convened by WHO and its partner Medicines Patent Pool (MPP). Five Working Groups (WG) are responsible for the design and coordination of the activities required to fulfill the objectives of the mRNA Technology Transfer Programme.

Working Group 1 – Technology selection, technical innovation, and IP
Working Group 2 – Product development, including clinical development, Manufacturing and Technology Transfer
Working Group 3 – Regulatory strengthening: support the development of regulatory capabilities and skilled workforce to facilitate regional approvals.
Working Group 4 – Business Modelling & Market shaping strategies/ policies
Working Group 5 – Programme Funding & Governance


A Scientific and Technical Review Committee (STeRCO) of independent experts and stakeholders supports the WHO secretariat on aspects of critical importance to the successful accomplishment of the objectives of the mRNA Technology Transfer Programme.

Additionally, a mRNA Scientific Advisory Committee (mSAC) convened by MPP comprising of experts in mRNA vaccine development provides technical input into the programme.

The mRNA Technology Transfer Programme operates in close cooperation with the Biomanufacturing training initiative coordinated by WHO and the WHO Academy, to align training needs for both hub and partners (manufacturing, good practices, technology transfer) and training offer.

Share page: